We are live on ! Find out more
State of Wisconsin Investment Board

State of Wisconsin Investment Board Portfolio holdings

AUM $43.7B
1-Year Est. Return 27.76%
This Fund
S&P 500
This Quarter Est. Return
+5.05%
1 Year Est. Return
+27.76%
3 Year Est. Return
+95.56%
5 Year Est. Return
+123.77%
10 Year Est. Return
+486.44%
AUM
$33.8B
AUM Growth
+$2.87B
Cap. Flow
+$1.54B
Cap. Flow %
4.54%
Top 10 Hldgs %
16.03%
Holding
1,494
New
35
Increased
872
Reduced
242
Closed
39

Sector Composition

Rank Sector Weight
1 Financials 17.53%
2 Technology 16.04%
3 Healthcare 13.34%
4 Industrials 10.24%
5 Communication Services 9.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CNA icon
1376
CNA Financial
CNA
$13.7B
$276K ﹤0.01%
5,492
+82
+2% +$4.1K
TVRD
1377
Tvardi Therapeutics
TVRD
$22.4M
$274K ﹤0.01%
556
NVTA
1378
DELISTED
Invitae Corporation
NVTA
$272K ﹤0.01%
29,000
KANG
1379
DELISTED
iKang Healthcare Group, Inc.
KANG
$270K ﹤0.01%
20,000
BHVN
1380
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$262K ﹤0.01%
+7,000
New +$212K
BKI
1381
DELISTED
Black Knight, Inc. Common Stock
BKI
$252K ﹤0.01%
5,855
+127
+2% +$5.39K
NTLA icon
1382
Intellia Therapeutics
NTLA
$1.67B
$248K ﹤0.01%
10,000
IR icon
1383
Ingersoll Rand
IR
$32.4B
$241K ﹤0.01%
+8,769
New +$206K
MCRB icon
1384
Seres Therapeutics
MCRB
$44.9M
$241K ﹤0.01%
750
GERN icon
1385
Geron
GERN
$1.01B
$240K ﹤0.01%
110,000
SEB icon
1386
Seaboard Corp
SEB
$4.11B
$239K ﹤0.01%
53
-7
-12% -$29.9K
AGEN
1387
Agenus
AGEN
$314M
$234K ﹤0.01%
2,700
PGEN icon
1388
Precigen
PGEN
$2.37B
$234K ﹤0.01%
12,293
+1,611
+15% +$33.2K
ADMS
1389
DELISTED
Adamas Pharmaceuticals
ADMS
$233K ﹤0.01%
11,000
-100,000
-90% -$1.83M
BLCM
1390
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$231K ﹤0.01%
2,000
CRBP icon
1391
Corbus Pharmaceuticals
CRBP
$193M
$229K ﹤0.01%
1,067
NVAX icon
1392
Novavax
NVAX
$1.34B
$228K ﹤0.01%
10,000
SCMP
1393
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$224K ﹤0.01%
19,000
RIGL icon
1394
Rigel Pharmaceuticals
RIGL
$761M
$216K ﹤0.01%
8,500
FMX icon
1395
Fomento Económico Mexicano
FMX
$39.9B
$213K ﹤0.01%
+2,227
New +$222K
ICPT
1396
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$211K ﹤0.01%
3,642
+75
+2% +$8.08K
TLGT
1397
DELISTED
Teligent, Inc
TLGT
$208K ﹤0.01%
3,100
VYGR icon
1398
Voyager Therapeutics
VYGR
$198M
$206K ﹤0.01%
10,000
CIG icon
1399
CEMIG Preferred Shares
CIG
$5.52B
$193K ﹤0.01%
152,816
-342,592
-69% -$467K
CNCE
1400
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$192K ﹤0.01%
13,000

Similar funds

State of Wisconsin Investment Board's Q3 2017 Portfolio in Review

As of Q3 2017, State of Wisconsin Investment Board held 1,494 positions worth $33.8B, up 9.2% from $31B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

State of Wisconsin Investment Board deployed $1.54B of net new capital in Q3 2017, opening 35 new positions and adding to 872 existing holdings. Its largest new stake was Discovery, Inc. Series C Common Stock: 6,728,154 shares worth $136M.

By sector, the portfolio is most concentrated in Financials at 18% of assets, up from 17% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Alphabet (Google) Class C, an estimated $254M trimmed.

  • State of Wisconsin Investment Board's largest Q3 2017 buy was Discovery, Inc. Series C Common Stock: 6,728,154 shares worth $136M.
  • State of Wisconsin Investment Board added most to Alphabet (Google) Class A in Q3 2017, an estimated $273M increase.
  • State of Wisconsin Investment Board's biggest Q3 2017 reduction was Alphabet (Google) Class C, cutting an estimated $254M.
  • State of Wisconsin Investment Board fully exited Du Pont De Nemours E I in Q3 2017, selling an estimated $89.3M.
  • State of Wisconsin Investment Board's ten largest holdings make up 16% of its $33.8B portfolio in Q3 2017.
  • State of Wisconsin Investment Board opened 35 new positions and closed 39 in Q3 2017.
  • State of Wisconsin Investment Board's portfolio value rose 9.2% quarter-over-quarter to $33.8B.

Based on State of Wisconsin Investment Board's 13F filing for Q3 2017, filed 1 Nov 2017.